RE:Biotech M&A is picking back up according to BiopharmaDiveWhile M&A took a back seat during the COVID-19 pandemic and the uncertain times that followed pharma companies ultimately need to return to their dealmaking ways to remain profitable, said Jennifer O’Brien, an M&A partner at the consulting firm West Monroe.
And while the biotech giant Biogen has had some missteps and hurdles, one move in particular may foretell a brighter future, analysts say: July’s announced $7.3 billion acquisition of Reata Pharmaceuticals, a small Texas company with one approved drug — Skyclarys — for a rare nervous system disease called Friedreich’s ataxia.
https://www.pharmavoice.com/news/biogen-reata-acquisition-MA-biopharma/690460/